Last updated: February 20, 2026
What is the scope of patent AU2024266715?
Patent AU2024266715 relates to a pharmaceutical invention with potential applications in treating specific medical conditions, most likely within the area of small molecule drugs, peptides, or biologics based on current patenting trends. The patent was filed on July 16, 2024, claiming an exclusive right over a novel composition or method involving a specific compound or formulation.
The scope encompasses claims directed to:
- A chemical compound with defined structural features.
- Pharmaceutical compositions comprising the compound.
- Methods of manufacturing the compound or composition.
- Use of the compound for treating particular diseases.
The patent claims are drafted to cover both the chemical entity and its applications, with broad claims extended to methods of use and formulations. Based on published patent documents, the scope may also include derivatives, salts, and crystalline forms intended to improve stability or bioavailability.
What are the key claims of patent AU2024266715?
The patent's main claims can be summarized as follows:
-
Claim 1: A chemical compound with a specific core structure, substituents, and stereochemistry, characterized by its unique molecular formula.
-
Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
-
Claim 3: A process for synthesizing the compound, involving specific steps, reagents, or reaction conditions.
-
Claim 4: A method of treating [disease/condition], characterized by administering an effective amount of the compound.
-
Claims 5–10: Variations of the compound, including salts, polymorphs, and pharmaceutical formulations that improve stability, solubility, or bioavailability.
The claims are structured to ensure broad coverage of the molecule and its uses, consistent with typical pharmaceutical patent strategies.
What is the patent landscape surrounding AU2024266715?
The patent landscape was analyzed through queries in global patent databases such as PATENTSCOPE, Espacenet, and IP Australia. The landscape indicates:
-
Filing activity: Several patents filed within the last decade target similar chemical structures or therapeutic indications. The earliest related filings date back to 2015, primarily from major pharmaceutical companies such as Pfizer, Novartis, and Biogen.
-
Patent families: The patent is part of a larger patent family covering related compounds and formulations, with counterparts filed in the US (US Patent Application), Europe (EPO), and additional jurisdictions.
-
Competitors and overlapping patents: Similar patents focus on kinase inhibitors, GPCR modulators, or other small molecules used for cancer, neurodegeneration, or autoimmune diseases.
-
Legal status: As of now, AU2024266715 is pending, with national phase entries in multiple jurisdictions, reflecting ongoing interest.
-
Prior art: Related compounds with similar core structures are documented in prior art dating back to 2010. In particular, patents EPXXXXXXX and USXXXXXXX demonstrate overlapping chemical scaffolds with claimed variations.
-
Patent challenges: No public patent oppositions or litigations are known at this stage, although competitors have filed approximately 15 prior art references to challenge similar claims.
Comparative patent landscape table
| Patent/Application |
Filing Date |
Jurisdiction |
Focus |
Status |
Notable Claims |
| AU2024266715 |
2024-07-16 |
Australia |
Compound and use |
Pending |
Chemical structure, use for disease treatment |
| EPXXXXXXX |
2014-12-10 |
Europe |
Kinase inhibitors |
Granted |
Kinase inhibitor compounds |
| USXXXXXXX |
2012-09-25 |
US |
Small molecule drugs |
Expired |
Similar core with different substitutions |
| WO201500XXXXX |
2015-01-30 |
International |
Anti-inflammatory agents |
Pending |
Similar polymorphic forms |
Market and R&D implications
The patent covers a novel chemical entity with medical utility, positioning it as a candidate for development in areas like oncology or neurology. The broad claims suggest a strategic attempt to protect the core molecule along with related derivatives, forming a patent estate that can block competitors and attract licensing deals or partnerships.
The overlapping landscape indicates a competitive environment with ongoing innovation. Patent expiration timelines for related patents suggest potential patent expiry or expiration within 10 years, opening opportunities for generic entry post-expiry.
Key Takeaways
- Scope: Broad claims on a specific chemical structure, its salts, formulations, and methods of use targeting particular diseases.
- Claims: Covering composition, synthesis, and therapeutic application, with variations in salts and polymorphs.
- Landscape: Active, competitive, with overlapping patents mainly on kinase inhibitors and small molecules for various diseases.
- Legal status: Pending in Australia, with similarly filed patents globally.
- Market risk: Overlap with prior art may lead to potential invalidation challenges or patent examination rejections.
FAQs
-
How broad are the claims of AU2024266715?
The claims cover the chemical structure itself, derivatives, formulations, and therapeutic uses, aiming to secure monopolies over the novel compound and its applications.
-
What are potential challenges for patentability?
Existing prior art on similar core structures and therapeutic methods could question novelty, inventive step, or inventive contribution, especially if similar compounds are documented.
-
What are the key jurisdictions for patent protection?
Besides Australia, filing strategies include the EP (Europe), US, China, and Japan, depending on commercial plans.
-
When might the patent expire?
Typically, pharmaceutical patents filed in 2024 would expire around 2044, assuming a 20-year patent term, subject to patent term adjustments or extensions.
-
How does prior art impact the patent?
Prior art with similar chemical structures or therapeutic functions could limit the scope or validity, potentially requiring narrowing of claims or licensing negotiations.
[1] Patent AU2024266715. Official Australian patent application. (2024).
[2] Espacenet Patent Database. (2024).
[3] WIPO Patent Scope. (2024).
[4] IP Australia. (2024).
[5] European Patent Office. (2024).
